GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Omeros Corporation (OMER) [hlAlert]

Rating:
Mkt Outperform
OMER
up 45.52 %

Omeros Corporation (OMER) rated Mkt Outperform with price target $16 by Burrill Institutional Research

Posted on: Friday,  Dec 28, 2012  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Omeros Corporation (NASDAQ: OMER) on 12/28/2012. Previously Burrill Institutional Research rated Mkt Outperform Omeros Corporation (NASDAQ: OMER)
on 10/15/2012., when the stock price was $10.83. Since then, Omeros Corporation has gained 45.52% as of 01/26/2016's recent price of $15.76.
If you would have followed the previous Burrill Institutional Research's recommendation on OMER, you would have gained 45.52% of your investment in 1198 days.

Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company?s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/28/2012 8:25 AM Buy
None
5.65 16.00
as of 12/31/2012
1 Week down  -14.63 %
1 Month down  -30.61 %
3 Months down  -8.14 %
1 YTD down  -8.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/15/2012 8:25 AM Buy
None
10.83 17.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy